Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

Exclusion Criteria

• •Uncontrolled hypertriglyceridemia.
• •Guttate, erythrodermic, or pustular psoriasis.
• •Severely impaired hepatic function, \> 3 times the upper limit of normal and the clinical investigator's judgment.
• •Use of systemic immunosuppressant agents (eg. Methotrexate, cyclosporine, thioguanine, azathioprine, alefacept, egalizumab, corticosteroids) within 4 weeks of baseline and throughout the study.
• •Topical vitamin A, vitamin D or analogue preparations, or anthralin within 2 weeks of study initiation.
• •History of known or suspected intolerance to any of the ingredients of the investigational study product.
• •Used over the counter (non-prescription) medications or herbal remedies within 2 weeks of dosing, unless agreed upon as not clinically relevant by the principal investigator.
• •Participated in a previous study of the same study product.
• •Currently using any medication which, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk.
• •Currently suffering from any disease or condition which, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk.
• •Any major illness within 30 days before screening examination.
• •Considered immunocompromised.
• •A clinically relevant history of or current evidence of abuse of alcohol or other drugs.
• •Use of any investigational drugs or treatments during the study or within 4 weeks of the baseline visit.